{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:06:37Z","timestamp":1790193997780,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":113,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_855","type":"book-chapter","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:38:25Z","timestamp":1790192305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Introduction to PBPK Modelling: Core Concepts for Small and Large Molecules"],"prefix":"10.1007","author":[{"given":"Armin","family":"Sepp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"7","key":"855_CR1","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.chembiol.2021.02.024","volume":"28","author":"G Ahn","year":"2021","unstructured":"Ahn G, Banik SM, Bertozzi CR (2021) Degradation from the outside in: targeting extracellular and membrane proteins for degradation through the endolysosomal pathway. Cell Chem Biol 28(7):1072\u20131080","journal-title":"Cell Chem Biol"},{"issue":"1","key":"855_CR2","doi-asserted-by":"crossref","first-page":"13696","DOI":"10.1038\/s41598-020-70680-0","volume":"10","author":"MM Al Qaraghuli","year":"2020","unstructured":"Al Qaraghuli MM, Kubiak-Ossowska K, Ferro VA, Mulheran PA (2020) Antibody-protein binding and conformational changes: identifying allosteric signalling pathways to engineer a better effector response. Sci Rep 10(1):13696","journal-title":"Sci Rep"},{"issue":"11","key":"855_CR3","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24112159","volume":"24","author":"S Almahmoud","year":"2019","unstructured":"Almahmoud S, Wang X, Vennerstrom JL, Zhong HA (2019) Conformational studies of glucose transporter 1 (GLUT1) as an anticancer drug target. Molecules 24(11):2159","journal-title":"Molecules"},{"issue":"2","key":"855_CR4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jcph.804","volume":"57","author":"G An","year":"2017","unstructured":"An G (2017) Small-molecule compounds exhibiting target-mediated drug disposition (TMDD): a minireview. J Clin Pharmacol 57(2):137\u2013150","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"855_CR5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bcp.15990","volume":"90","author":"S Armani","year":"2024","unstructured":"Armani S, Geier A, Forst T, Merle U, Alpers DH, Lunnon MW (2024) Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug\u2013drug interactions. Br J Clin Pharmacol 90(4):942\u2013958","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"855_CR6","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","volume":"23","author":"VR Aroda","year":"2022","unstructured":"Aroda VR, Blonde L, Pratley RE (2022) A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord 23(5):979\u2013994","journal-title":"Rev Endocr Metab Disord"},{"key":"855_CR7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-022-06012-3","volume":"50","author":"TA Aweda","year":"2023","unstructured":"Aweda TA, Cheng S-H, Lenhard SC, Sepp A, Skedzielewski T, Hsu C-Y, Marshall S, Haag H, Kehler J, Jagdale P et al (2023) In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging 50:667\u2013678","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"855_CR8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s11095-022-03391-y","volume":"40","author":"A Bauer","year":"2023","unstructured":"Bauer A, Berben P, Chakravarthi SS, Chattorraj S, Garg A, Gourdon B, Heimbach T, Huang Y, Morrison C, Mundhra D et al (2023) Current state and opportunities with long-acting Injectables: industry perspectives from the innovation and quality consortium \u201clong-acting Injectables\u201d working group. Pharm Res 40(7):1601\u20131631","journal-title":"Pharm Res"},{"issue":"5","key":"855_CR9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/bcp.12875","volume":"81","author":"G Bernadou","year":"2016","unstructured":"Bernadou G, Campone M, Merlin J-L, Gouilleux-Gruart V, Bachelot T, Lokiec F, Rezai K, Arnedos M, Di\u00e9ras V, Jimenez M et al (2016) Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. Br J Clin Pharmacol 81(5):941\u2013948","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"855_CR10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/19420862.2018.1462429","volume":"10","author":"A Betts","year":"2018","unstructured":"Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, Berkhout J (2018) Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. MAbs 10(5):751\u2013764","journal-title":"MAbs"},{"issue":"8","key":"855_CR11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/dmd.116.070763","volume":"44","author":"MA Cerny","year":"2016","unstructured":"Cerny MA (2016) Prevalence of non-cytochrome P450-mediated metabolism in Food and Drug Administration-approved Oral and intravenous drugs: 2003\u20132013. Drug Metab Dispos 44(8):1246\u20131252","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"855_CR12","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1073\/pnas.0610494104","volume":"104","author":"C-eA Chang","year":"2007","unstructured":"Chang C-eA, Chen W, Gilson MK (2007) Ligand configurational entropy and protein binding. Proc Natl Acad Sci 104(5):1534\u20131539","journal-title":"Proc Natl Acad Sci"},{"key":"855_CR13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fphar.2014.00258","volume":"5","author":"M Chetty","year":"2014","unstructured":"Chetty M, Rose R, Abduljalil K, Patel N, Lu G, Cain T, Jamei M, Rostami-Hodjegan A (2014) Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. Front Pharmacol 5:258","journal-title":"Front Pharmacol"},{"issue":"3","key":"855_CR14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","volume":"35","author":"ST Crooke","year":"2017","unstructured":"Crooke ST, Wang S, Vickers TA, Shen W, Liang X-H (2017) Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol 35(3):230\u2013237","journal-title":"Nat Biotechnol"},{"issue":"9","key":"855_CR15","first-page":"1429","volume":"13","author":"L Curry","year":"2024","unstructured":"Curry L, Alrubia S, Bois FY, Clayton R, El-Khateeb E, Johnson TN, Faisal M, Neuhoff S, Wragg K, Rostami-Hodjegan A (2024) A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp simulator. CPT: Pharmacometr Syst Pharmacol 13(9):1429\u20131447","journal-title":"CPT: Pharmacometr Syst Pharmacol"},{"issue":"1","key":"855_CR16","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1770028","volume":"12","author":"A Datta-Mannan","year":"2020","unstructured":"Datta-Mannan A, Estwick S, Zhou C, Choi H, Douglass NE, Witcher DR, Lu J, Beidler C, Millican R (2020) Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies. MAbs 12(1):1770028","journal-title":"MAbs"},{"key":"855_CR17","doi-asserted-by":"publisher","unstructured":"Davis JD, Bravo Padros M, Conrado DJ, Ganguly S, Guan X, Hassan HE, Hazra A, Irvin SC, Jayachandran P, Kosloski MP et al (2023) Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.3150","DOI":"10.1002\/cpt.3150"},{"issue":"24","key":"855_CR18","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1113\/JP274819","volume":"595","author":"MJ Eigenmann","year":"2017","unstructured":"Eigenmann MJ, Karlsen TV, Krippendorff B-F, Tenstad O, Fronton L, Otteneder MB, Wiig H (2017a) Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches. J Physiol 595(24):7311\u20137330","journal-title":"J Physiol"},{"issue":"6","key":"855_CR19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/19420862.2017.1337619","volume":"9","author":"MJ Eigenmann","year":"2017","unstructured":"Eigenmann MJ, Fronton L, Grimm HP, Otteneder MB, Krippendorff B-F (2017b) Quantification of IgG monoclonal antibody clearance in tissues. MAbs 9(6):1007\u20131015","journal-title":"MAbs"},{"issue":"2","key":"855_CR20","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1152\/ajpendo.2000.278.2.E352","volume":"278","author":"M Ellmerer","year":"2000","unstructured":"Ellmerer M, Schaupp L, Brunner GA, Sendlhofer G, Wutte A, Wach P, Pieber TR (2000) Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am J Physiol-Endocrinol Metab 278(2):E352\u2013E356","journal-title":"Am J Physiol-Endocrinol Metab"},{"issue":"8","key":"855_CR21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104427","volume":"30","author":"S Esposito","year":"2025","unstructured":"Esposito S, Cebri\u00e1n D (2025) Translational PBPK\/PD modeling in drug discovery: a CRO perspective. Drug Discov Today 30(8):104427","journal-title":"Drug Discov Today"},{"issue":"8","key":"855_CR22","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1021\/acs.analchem.5b03900","volume":"88","author":"Y-Y Fan","year":"2016","unstructured":"Fan Y-Y, Neubert H (2016) Quantitative analysis of human neonatal fc receptor (FcRn) tissue expression in transgenic mice by online peptide Immuno-affinity LC-HRMS. Anal Chem 88(8):4239\u20134247","journal-title":"Anal Chem"},{"issue":"8","key":"855_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/biom9080373","volume":"9","author":"YY Fan","year":"2019","unstructured":"Fan YY, Farrokhi V, Caiazzo T, Wang M, O\u2019Hara DM, Neubert H (2019) Human FcRn tissue expression profile and half-life in PBMCs. Biomolecules 9(8):373","journal-title":"Biomolecules"},{"issue":"10","key":"855_CR24","doi-asserted-by":"crossref","first-page":"105173","DOI":"10.1016\/j.isci.2022.105173","volume":"25","author":"J Feng","year":"2022","unstructured":"Feng J, Jiang M, Shih J, Chai Q (2022) Antibody apparent solubility prediction from sequence by transfer learning. iScience 25(10):105173","journal-title":"iScience"},{"issue":"1","key":"855_CR25","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","volume":"15","author":"S Foss","year":"2024","unstructured":"Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, Scheepmaker L, Mathiesen L, Ruso-Julve F, Anthi AK et al (2024) Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nat Commun 15(1):2007","journal-title":"Nat Commun"},{"issue":"22","key":"855_CR26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216224","volume":"24","author":"L Gaohua","year":"2023","unstructured":"Gaohua L, Zhang M, Sychterz C, Chang M, Schmidt BJ (2023) The interplay of permeability, metabolism, transporters, and dosing in determining the dynamics of the tissue\/plasma partition coefficient and volume of distribution\u2014a theoretical investigation using permeability-limited, physiologically based pharmacokinetic modeling. Int J Mol Sci 24(22):16224","journal-title":"Int J Mol Sci"},{"key":"855_CR27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1208\/s12248-015-9819-4","volume":"18","author":"K Gill","year":"2015","unstructured":"Gill K, Gardner I, Li L, Jamei M (2015) A bottom-up whole-body physiologically based pharmacokinetic model to mechanistically predict tissue distribution and the rate of subcutaneous absorption of therapeutic proteins. AAPS J 18:156\u2013170","journal-title":"AAPS J"},{"key":"855_CR28","first-page":"1","volume-title":"Biology of cardiovascular and metabolic diseases","author":"C Gopalan","year":"2022","unstructured":"Gopalan C, Kirk E: Chapter 1: The heart. In: Biology of cardiovascular and metabolic diseases. Gopalan C, Kirk E: Academic; 2022: 1\u201333"},{"issue":"2","key":"855_CR29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-019-00834-5","volume":"59","author":"H Haahr","year":"2020","unstructured":"Haahr H, Heise T (2020) Fast-acting insulin Aspart: a review of its pharmacokinetic and Pharmacodynamic properties and the clinical consequences. Clin Pharmacokinet 59(2):155\u2013172","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"855_CR30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/intimm\/dxv012","volume":"27","author":"KC Hansen","year":"2015","unstructured":"Hansen KC, D\u2019Alessandro A, Clement CC, Santambrogio L (2015) Lymph formation, composition and circulation: a proteomics perspective. Int Immunol 27(5):219\u2013227","journal-title":"Int Immunol"},{"issue":"6","key":"855_CR31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/00365521.2014.898326","volume":"49","author":"HF Helander","year":"2014","unstructured":"Helander HF, F\u00e4ndriks L (2014) Surface area of the digestive tract\u2014revisited. Scand J Gastroenterol 49(6):681\u2013689","journal-title":"Scand J Gastroenterol"},{"issue":"36","key":"855_CR32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/cen-10136-cover","volume":"101","author":"L Howes","year":"2023","unstructured":"Howes L (2023) Is this a golden age of small-molecule drug discovery? C&EN Glob Enterprise 101(36):28\u201332","journal-title":"C&EN Glob Enterprise"},{"key":"855_CR33","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fphar.2020.00524","volume":"11","author":"S Hua","year":"2020","unstructured":"Hua S (2020) Advances in Oral drug delivery for regional targeting in the gastrointestinal tract \u2013 influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol 11:524","journal-title":"Front Pharmacol"},{"issue":"5","key":"855_CR34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063236","volume":"8","author":"T Igawa","year":"2013","unstructured":"Igawa T, Maeda A, Haraya K, Tachibana T, Iwayanagi Y, Mimoto F, Higuchi Y, Ishii S, Tamba S, Hironiwa N et al (2013) Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One 8(5):e63236","journal-title":"PLoS One"},{"key":"855_CR35","unstructured":"Institute TI: The Global Use of Medicines 2024: Outlook to 2028. In; 2024: 60"},{"issue":"6","key":"855_CR36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235076","volume":"15","author":"Y Ionova","year":"2020","unstructured":"Ionova Y, Wilson L (2020) Biologic excipients: importance of clinical awareness of inactive ingredients. PLoS One 15(6):e0235076","journal-title":"PLoS One"},{"issue":"2","key":"855_CR37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.00942-08","volume":"53","author":"JM Jacobson","year":"2009","unstructured":"Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST (2009) Safety, pharmacokinetics, and antiretroviral activity of multiple doses of Ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 53(2):450\u2013457","journal-title":"Antimicrob Agents Chemother"},{"key":"855_CR38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10928-022-09824-w","volume":"49","author":"P Jagdale","year":"2022","unstructured":"Jagdale P, Sepp A, Shah DK (2022) Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans. J Pharmacokinet Pharmacodyn 49:607\u2013624","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"855_CR39","first-page":"75","volume":"9","author":"M Jamei","year":"2020","unstructured":"Jamei M (2020) Where do PBPK models stand in Pharmacometrics and systems pharmacology? CPT: Pharmacometr Syst Pharmacol 9(2):75\u201376","journal-title":"CPT: Pharmacometr Syst Pharmacol"},{"issue":"1","key":"855_CR40","doi-asserted-by":"crossref","DOI":"10.1186\/2193-9616-1-9","volume":"1","author":"M Jamei","year":"2013","unstructured":"Jamei M, Marciniak S, Edwards D, Wragg K, Feng K, Barnett A, Rostami-Hodjegan A (2013) The Simcyp population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacol 1(1):9","journal-title":"In Silico Pharmacol"},{"key":"855_CR41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fphys.2021.753833","volume":"12","author":"BH James","year":"2022","unstructured":"James BH, Papakyriacou P, Gardener MJ, Gliddon L, Weston CJ, Lalor PF (2022) The contribution of liver sinusoidal endothelial cells to clearance of therapeutic antibody. Front Physiol 12:12","journal-title":"Front Physiol"},{"issue":"4","key":"855_CR42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.xphs.2021.11.008","volume":"111","author":"W Jiskoot","year":"2022","unstructured":"Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA (2022) Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: quo Vadis? J Pharm Sci 111(4):861\u2013867","journal-title":"J Pharm Sci"},{"issue":"10","key":"855_CR43","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1023\/A:1015040217741","volume":"16","author":"J Kelder","year":"1999","unstructured":"Kelder J, Grootenhuis PDJ, Bayada DM, Delbressine LPC, Ploemen J-P (1999) Polar molecular surface as a dominating determinant for Oral absorption and brain penetration of drugs. Pharm Res 16(10):1514\u20131519","journal-title":"Pharm Res"},{"issue":"2","key":"855_CR44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clim.2006.09.001","volume":"122","author":"J Kim","year":"2007","unstructured":"Kim J, Hayton WL, Robinson JM, Anderson CL (2007) Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol 122(2):146\u2013155","journal-title":"Clin Immunol"},{"key":"855_CR45","doi-asserted-by":"publisher","unstructured":"Li Z, Krippendorff BF, Sharma S, Walz AC, Lave T, Shah DK (2016) Influence of molecular size on tissue distribution of antibody fragments. MAbs. https:\/\/doi.org\/10.1080\/19420862.2015.1111497","DOI":"10.1080\/19420862.2015.1111497"},{"issue":"3","key":"855_CR46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1208\/s12248-021-00588-8","volume":"23","author":"Z Li","year":"2021","unstructured":"Li Z, Yu X, Li Y, Verma A, Chang HP, Shah DK (2021) A two-pore physiologically based pharmacokinetic model to predict subcutaneously administered different-size antibody\/antibody fragments. AAPS J 23(3):62","journal-title":"AAPS J"},{"issue":"11","key":"855_CR47","volume":"17","author":"Y Li","year":"2025","unstructured":"Li Y, Sun H, Zhang Z (2025) The evolution and future directions of PBPK modeling in FDA regulatory review. Pharmaceutics 17(11):1413","journal-title":"Pharmaceutics"},{"issue":"11","key":"855_CR48","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/pharmaceutics12111025","volume":"12","author":"W Liang","year":"2020","unstructured":"Liang W, Pan HW, Vllasaliu D, Lam JKW (2020) Pulmonary delivery of biological drugs. Pharmaceutics 12(11):1025","journal-title":"Pharmaceutics"},{"issue":"8","key":"855_CR49","volume":"10","author":"XP Lin","year":"2020","unstructured":"Lin XP, Mintern JD, Gleeson PA (2020) Macropinocytosis in different cell types: similarities and differences. Membranes (Basel) 10(8):177","journal-title":"Membranes (Basel)"},{"issue":"1\u20133","key":"855_CR50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1\u20133):3\u201326","journal-title":"Adv Drug Deliv Rev"},{"key":"855_CR51","doi-asserted-by":"crossref","first-page":"1088458","DOI":"10.3389\/fonc.2022.1088458","volume":"12","author":"W Liu","year":"2023","unstructured":"Liu W, Li J, Zhao R, Lu Y, Huang P (2023) The Uridine diphosphate (UDP)-glycosyltransferases (UGTs) superfamily: the role in tumor cell metabolism. Front Oncologia 12:1088458","journal-title":"Front Oncologia"},{"key":"855_CR52","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10928-024-09922-x","volume":"51","author":"S Liu","year":"2024","unstructured":"Liu S, Li Y, Li Z, Wu S, Harrold JM, Shah DK (2024) Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins. J Pharmacokinet Pharmacodyn 51:449\u2013476","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"855_CR53","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s40262-023-01270-2","volume":"62","author":"S Lobet","year":"2023","unstructured":"Lobet S, Paintaud G, Azzopardi N, Passot C, Caulet M, Chautard R, Desvignes C, Capitain O, Tougeron D, Lecomte T et al (2023) Relationship between Cetuximab target-mediated pharmacokinetics and progression-free survival in metastatic colorectal cancer patients. Clin Pharmacokinet 62:1263","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"855_CR54","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1038\/s41467-022-31457-3","volume":"13","author":"EK Makowski","year":"2022","unstructured":"Makowski EK, Kinnunen PC, Huang J, Wu L, Smith MD, Wang T, Desai AA, Streu CN, Zhang Y, Zupancic JM et al (2022) Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. Nat Commun 13(1):3788","journal-title":"Nat Commun"},{"issue":"2","key":"855_CR55","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1039\/C2CS35348B","volume":"42","author":"DT Manallack","year":"2013","unstructured":"Manallack DT, Prankerd RJ, Yuriev E, Oprea TI, Chalmers DK (2013) The significance of acid\/base properties in drug discovery. Chem Soc Rev 42(2):485\u2013496","journal-title":"Chem Soc Rev"},{"issue":"7","key":"855_CR56","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1021\/cb300119g","volume":"7","author":"PJ McEnaney","year":"2012","unstructured":"McEnaney PJ, Parker CG, Zhang AX, Spiegel DA (2012) Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol 7(7):1139\u20131151","journal-title":"ACS Chem Biol"},{"issue":"10","key":"855_CR57","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.4c00132","volume":"21","author":"M Milewski","year":"2024","unstructured":"Milewski M, Murashov M, Kapoor Y, Zhang J, Zhu W, Cueto MA, Buist N (2024) Predicting human subcutaneous bioavailability of therapeutic monoclonal antibodies from systemic clearance and volume of distribution. Mol Pharm 21(10):4947\u20134959","journal-title":"Mol Pharm"},{"issue":"9\u201310","key":"855_CR58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020","volume":"17","author":"P Morgan","year":"2012","unstructured":"Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SDA (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17(9\u201310):419\u2013424","journal-title":"Drug Discov Today"},{"key":"855_CR59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","volume":"17","author":"P Morgan","year":"2018","unstructured":"Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, Fidock M, Hamren B, Johnson A, March RE et al (2018) Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov 17:167","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"855_CR60","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/cts.13278","volume":"15","author":"M Muliaditan","year":"2022","unstructured":"Muliaditan M, Sepp A (2022) Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies. Clin Transl Sci 15(7):1634\u20131643","journal-title":"Clin Transl Sci"},{"issue":"1612","key":"855_CR61","doi-asserted-by":"crossref","first-page":"20120431","DOI":"10.1098\/rstb.2012.0431","volume":"368","author":"DW Nebert","year":"2013","unstructured":"Nebert DW, Wikvall K, Miller WL (2013) Human cytochromes P450 in health and disease. Philos Trans R Soc B: Biol Sci 368(1612):20120431","journal-title":"Philos Trans R Soc B: Biol Sci"},{"issue":"2","key":"855_CR62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.59566\/IJBS.2006.2085","volume":"2","author":"LA Nguyen","year":"2006","unstructured":"Nguyen LA, He H, Pham-Huy C (2006) Chiral drugs: an overview. Int J Biomed Sci 2(2):85\u2013100","journal-title":"Int J Biomed Sci"},{"key":"855_CR63","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.csbj.2025.05.036","volume":"27","author":"S Park","year":"2025","unstructured":"Park S, Song S-S, Jung W, Yun H-y, Lee S, Kang S-W, Chae J-W (2025) Mechanistic in vitro\u2013in vivo extrapolation (IVIVE) approach using a biomimetic in vitro system for the prediction of hepatic clearance. Comput Struct Biotechnol J 27:2424\u20132433","journal-title":"Comput Struct Biotechnol J"},{"issue":"3","key":"855_CR64","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0022-5193(63)90088-2","volume":"5","author":"CS Patlak","year":"1963","unstructured":"Patlak CS, Goldstein DA, Hoffman JF (1963) The flow of solute and solvent across a two-membrane system. J Theor Biol 5(3):426\u2013442","journal-title":"J Theor Biol"},{"issue":"3","key":"855_CR65","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cpt.3525","volume":"117","author":"P Paul","year":"2025","unstructured":"Paul P, Colin PJ, Musuamba Tshinanu F, Versantvoort C, Manolis E, Blake K (2025) Current use of physiologically based pharmacokinetic modeling in new medicinal product approvals at EMA. Clin Pharmacol Ther 117(3):808\u2013817","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"855_CR66","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10928-012-9260-6","volume":"39","author":"LA Peletier","year":"2012","unstructured":"Peletier LA, Gabrielsson J (2012) Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn 39(5):429\u2013451","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"855_CR67","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-015-0351-6","volume":"55","author":"SA Peters","year":"2016","unstructured":"Peters SA, Jones CR, Ungell A-L, Hatley OJD (2016) Predicting drug extraction in the human Gut Wall: assessing contributions from drug metabolizing enzymes and transporter proteins using preclinical models. Clin Pharmacokinet 55(6):673\u2013696","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"855_CR68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jps.10005","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91(1):129\u2013156","journal-title":"J Pharm Sci"},{"issue":"3","key":"855_CR69","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1208\/s12248-013-9470-x","volume":"15","author":"T Prueksaritanont","year":"2013","unstructured":"Prueksaritanont T, Chu X, Gibson C, Cui D, Yee KL, Ballard J, Cabalu T, Hochman J (2013) Drug\u2013drug interaction studies: regulatory guidance and an industry perspective. AAPS J 15(3):629\u2013645","journal-title":"AAPS J"},{"issue":"1","key":"855_CR70","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2085535","volume":"14","author":"H Rafidi","year":"2022","unstructured":"Rafidi H, Rajan S, Urban K, Shatz-Binder W, Hui K, Ferl GZ, Kamath AV, Boswell CA (2022) Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies. MAbs 14(1):2085535","journal-title":"MAbs"},{"key":"855_CR71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt.3625","volume":"118","author":"K Reynolds","year":"2025","unstructured":"Reynolds K, Yang X, Peters SA, Sinha V, Heymann H, Borges LN, Einolf HJ, Fu S, Hoshino M, Li L et al (2025) ICH M12 drug interaction studies: summary of the efforts to achieve global convergence. Clin Pharmacol Ther 118:33","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"855_CR72","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter WF, Bhansali SG, Morris ME (2012) Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14(3):559\u2013570","journal-title":"AAPS J"},{"issue":"5","key":"855_CR73","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/19420862.2018.1458808","volume":"10","author":"WF Richter","year":"2018","unstructured":"Richter WF, Christianson GJ, Frances N, Grimm HP, Proetzel G, Roopenian DC (2018) Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. MAbs 10(5):803\u2013813","journal-title":"MAbs"},{"issue":"1","key":"855_CR74","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1152\/physrev.1994.74.1.163","volume":"74","author":"B Rippe","year":"1994","unstructured":"Rippe B, Haraldsson B (1994) Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev 74(1):163\u2013219","journal-title":"Physiol Rev"},{"key":"855_CR75","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-1-0716-1554-6_8","volume-title":"Enzyme kinetics in drug metabolism: fundamentals and applications","author":"AG Roberts","year":"2021","unstructured":"Roberts AG (2021) The structure and mechanism of drug transporters. In: Nagar S, Argikar UA, Tweedie D (eds) Enzyme kinetics in drug metabolism: fundamentals and applications. Springer US, New York, pp 193\u2013234"},{"issue":"6","key":"855_CR76","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95(6):1238\u20131257","journal-title":"J Pharm Sci"},{"issue":"6","key":"855_CR77","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94(6):1259\u20131276","journal-title":"J Pharm Sci"},{"key":"855_CR78","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106774","volume":"191","author":"R Roskoski","year":"2023","unstructured":"Roskoski R (2023) Rule of five violations among the FDA-approved small molecule protein kinase inhibitors. Pharmacol Res 191:106774","journal-title":"Pharmacol Res"},{"issue":"5","key":"855_CR79","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BCJ20210584","volume":"480","author":"G Salloum","year":"2023","unstructured":"Salloum G, Bresnick AR, Backer JM (2023) Macropinocytosis: mechanisms and regulation. Biochem J 480(5):335\u2013362","journal-title":"Biochem J"},{"key":"855_CR80","first-page":"111","volume-title":"International review of cell and molecular biology","author":"L Santambrogio","year":"2018","unstructured":"Santambrogio L (2018) Chapter 4: The lymphatic fluid. In: Galluzzi L (ed) International review of cell and molecular biology, vol 337. Academic, pp 111\u2013133"},{"issue":"1","key":"855_CR81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI et al (2017) A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16(1):19\u201334","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"855_CR82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10928-014-9402-0","volume":"42","author":"A Sepp","year":"2015","unstructured":"Sepp A, Berges A, Sanderson A, Meno-Tetang G (2015) Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory. J Pharmacokinet Pharmacodyn 42(2):97\u2013109","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"855_CR83","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10928-019-09640-9","volume":"46","author":"A Sepp","year":"2019","unstructured":"Sepp A, Meno-Tetang G, Weber A, Sanderson A, Schon O, Berges A (2019) Computer-assembled cross-species\/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats. J Pharmacokinet Pharmacodyn 46(4):339\u2013359","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"855_CR84","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1832861","volume":"12","author":"A Sepp","year":"2020","unstructured":"Sepp A, Bergstr\u00f6m M, Davies M (2020) Cross-species\/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans. MAbs 12(1):e1832861","journal-title":"MAbs"},{"issue":"1","key":"855_CR85","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67\u201386","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"855_CR86","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.23684","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah DK, Betts AM (2013) Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5(2):297\u2013305","journal-title":"MAbs"},{"issue":"4","key":"855_CR87","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46(4):1584\u20131600","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"855_CR88","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28104014","volume":"28","author":"NI Sincere","year":"2023","unstructured":"Sincere NI, Anand K, Ashique S, Yang J, You C (2023) PROTACs: emerging targeted protein degradation approaches for advanced Druggable strategies. Molecules 28(10):4014","journal-title":"Molecules"},{"key":"855_CR89","doi-asserted-by":"publisher","unstructured":"Southey MWY, Brunavs M: Introduction to small molecule drug discovery and preclinical development. Front Drug Discovery 2023, 3, https:\/\/doi.org\/10.3389\/fddsv.2023.1314077","DOI":"10.3389\/fddsv.2023.1314077"},{"issue":"3","key":"855_CR90","doi-asserted-by":"crossref","DOI":"10.3390\/antib13030070","volume":"13","author":"F Stader","year":"2024","unstructured":"Stader F, Liu C, Derbalah A, Momiji H, Pan X, Gardner I, Jamei M, Sepp A (2024) A physiologically based pharmacokinetic model relates the subcutaneous bioavailability of monoclonal antibodies to the saturation of FcRn-mediated recycling in injection-site-draining lymph nodes. Antibodies 13(3):70","journal-title":"Antibodies"},{"issue":"7","key":"855_CR91","first-page":"1262","volume":"14","author":"R Straube","year":"2025","unstructured":"Straube R (2025) Target-mediated drug disposition (TMDD) revisited: high versus low-affinity approximations of the TMDD model. CPT: Pharmacometr Syst Pharmacol 14(7):1262\u20131272","journal-title":"CPT: Pharmacometr Syst Pharmacol"},{"key":"855_CR92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnins.2015.00021","volume":"9","author":"N Strazielle","year":"2015","unstructured":"Strazielle N, Ghersi-Egea J-F (2015) Efflux transporters in blood-brain interfaces of the developing brain. Front Neurosci 9:21","journal-title":"Front Neurosci"},{"issue":"4","key":"855_CR93","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","volume":"29","author":"WR Strohl","year":"2015","unstructured":"Strohl WR (2015) Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29(4):215\u2013239","journal-title":"BioDrugs"},{"key":"855_CR94","doi-asserted-by":"crossref","first-page":"1398059","DOI":"10.3389\/fnut.2024.1398059","volume":"11","author":"R Tamayo-Trujillo","year":"2024","unstructured":"Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ram\u00edrez P, Paz-Cruz E, Zambrano-Villacres R, Simancas-Racines D, Zambrano AK (2024) Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr 11:1398059","journal-title":"Front Nutr"},{"issue":"2","key":"855_CR95","first-page":"253","volume":"38","author":"SPF Tan","year":"2021","unstructured":"Tan SPF, Chan ECY, Chan JCY (2021) Predicting human tissue exposures to xenobiotics using a bottom-up physiologically-based biokinetic model. ALTEX\u2014Altern Anim Exp 38(2):253\u2013268","journal-title":"ALTEX\u2014Altern Anim Exp"},{"issue":"5","key":"855_CR96","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cpt.1693","volume":"107","author":"KS Taskar","year":"2020","unstructured":"Taskar KS, Pilla Reddy V, Burt H, Posada MM, Varma M, Zheng M, Ullah M, Emami Riedmaier A, Umehara K-i, al Snoeys J e (2020) Physiologically-based pharmacokinetic models for evaluating membrane transporter mediated drug\u2013drug interactions: current capabilities, case studies, future opportunities, and recommendations. Clin Pharmacol Ther 107(5):1082\u20131115","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"855_CR97","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s00535-015-1061-4","volume":"50","author":"T Terada","year":"2015","unstructured":"Terada T, Hira D (2015) Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles. J Gastroenterol 50(5):508\u2013519","journal-title":"J Gastroenterol"},{"issue":"12","key":"855_CR98","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12):1421\u20131434","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"855_CR99","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/00003495-198937060-00004","volume":"37","author":"PA Todd","year":"1989","unstructured":"Todd PA, Brogden RN (1989) Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs 37(6):871\u2013899","journal-title":"Drugs"},{"issue":"11","key":"855_CR100","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"I Usach","year":"2019","unstructured":"Usach I, Martinez R, Festini T, Peris J-E (2019) Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther 36(11):2986\u20132996","journal-title":"Adv Ther"},{"issue":"4","key":"855_CR101","doi-asserted-by":"crossref","first-page":"F605","DOI":"10.1152\/ajprenal.00171.2004","volume":"288","author":"D Venturoli","year":"2005","unstructured":"Venturoli D, Rippe B (2005) Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol \u2013 Renal Physiol 288(4):F605\u2013F613","journal-title":"Am J Physiol \u2013 Renal Physiol"},{"key":"855_CR102","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/pharmaceutics18010022","volume":"18","author":"A Verma","year":"2026","unstructured":"Verma A, Wu S, Shah DK (2026) Oral bioavailability of monoclonal antibody. Pharmaceutics 18:22","journal-title":"Pharmaceutics"},{"issue":"6","key":"855_CR103","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2174\/138920108786786402","volume":"9","author":"J Vlasak","year":"2008","unstructured":"Vlasak J, Ionescu R (2008) Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr Pharm Biotechnol 9(6):468\u2013481","journal-title":"Curr Pharm Biotechnol"},{"key":"855_CR104","volume":"10","author":"Y Wan","year":"2022","unstructured":"Wan Y, Zuo T (2022) Interplays between drugs and the gut microbiome. Gastroenterology Report 10:goac009","journal-title":"Gastroenterology Report"},{"issue":"12","key":"855_CR105","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1113\/jphysiol.2011.206136","volume":"589","author":"H Wiig","year":"2011","unstructured":"Wiig H (2011) Pathophysiology of tissue fluid accumulation in inflammation. J Physiol 589(12):2945\u20132953","journal-title":"J Physiol"},{"issue":"3","key":"855_CR106","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1152\/physrev.00037.2011","volume":"92","author":"H Wiig","year":"2012","unstructured":"Wiig H, Swartz MA (2012) Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 92(3):1005\u20131060","journal-title":"Physiol Rev"},{"issue":"11","key":"855_CR107","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","volume":"32","author":"JA Williams","year":"2004","unstructured":"Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios. Drug Metab Dispos 32(11):1201\u20131208","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"855_CR108","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/glycob\/10.12.1347","volume":"10","author":"A Wright","year":"2000","unstructured":"Wright A, Sato Y, Okada T, Chang KH, Endo T, Morrison SL (2000) In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10(12):1347\u20131355","journal-title":"Glycobiology"},{"issue":"23","key":"855_CR109","volume":"25","author":"K Wu","year":"2024","unstructured":"Wu K, Kwon SH, Zhou X, Fuller C, Wang X, Vadgama J, Wu Y (2024) Overcoming challenges in small-molecule drug bioavailability: a review of key factors and approaches. Int J Mol Sci 25(23):13121","journal-title":"Int J Mol Sci"},{"issue":"2","key":"855_CR110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-5173(99)00147-7","volume":"186","author":"LX Yu","year":"1999","unstructured":"Yu LX, Amidon GL (1999) A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186(2):119\u2013125","journal-title":"Int J Pharm"},{"issue":"11","key":"855_CR111","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1021\/acs.jmedchem.0c01720","volume":"64","author":"D Zhang","year":"2021","unstructured":"Zhang D, Wei C, Hop CECA, Wright MR, Hu M, Lai Y, Khojasteh SC, Humphreys WG (2021) Intestinal excretion, intestinal recirculation, and renal tubule reabsorption are underappreciated mechanisms that drive the distribution and pharmacokinetic behavior of small molecule drugs. J Med Chem 64(11):7045\u20137059","journal-title":"J Med Chem"},{"issue":"23","key":"855_CR112","volume":"22","author":"M Zhao","year":"2021","unstructured":"Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, al He L e (2021) Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci 22(23):12808","journal-title":"Int J Mol Sci"},{"issue":"2","key":"855_CR113","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/mabs.4.2.19387","volume":"4","author":"Y Zheng","year":"2012","unstructured":"Zheng Y, Tesar DB, Benincosa L, Birnb\u00f6ck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ et al (2012) Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs 4(2):243\u2013255","journal-title":"MAbs"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:38:40Z","timestamp":1790192320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":113,"URL":"https:\/\/doi.org\/10.1007\/164_2026_855","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"24 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}